United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes o

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of s

Israel - English - Ministry of Health

teva israel ltd - desmopressin acetate - tablets - desmopressin acetate 0.1 mg - desmopressin - desmopressin - desmopressin teva tablets are indicated for central diabetes insipidus, nocturnal enuresis ( in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. the treatment must be started befor the age of 65.

Israel - English - Ministry of Health

teva israel ltd - desmopressin acetate - tablets - desmopressin acetate 0.2 mg - desmopressin - desmopressin - desmopressin teva tablets are indicated for central diabetes insipidus, nocturnal enuresis ( in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. the treatment must be started befor the age of 65.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) -

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 15 microgram/ml (equivalent: desmopressin, qty 13.4 microgram/ml) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - mild and moderate haemophillia a and von willebrand?s disease: by intravenous infusion only, for the increase of factor viii levels in patients undergoing dental or minor surgery. not to be used in type iib von willebrand?s disease since platelet aggregation may be induced.,bleeding in patients with platelet dysfunction: treatment of excessive bleeding in patients with congenital or acquired clinical conditions associated with platelet dysfunction which is characterised by a prolonged bleeding time except glanzmann?s thrombasthenia or platelet cyclo-oxygenase deficiency.,examples are patients with uraemia, congenital or drug induced platelet dysfunction and patients undergoing cardiac surgery with cardiopulmonary bypass for prosthetic valve replacement or aorto-coronary bypass grafting especially when it is complicated by platelet function defects sufficient to prolong bleeding time despite relatively normal platelet cover. desmopressin acetate offers no benefit as routine therapy in patients having an uncomp

Malta - English - Medicines Authority

ferring ireland limited united drug house, magna drive magna business park, citywest road dublin 24 , ireland - desmopressin acetate - solution for injection - desmopressin acetate 4 µg/ml - pituitary and hypothalamic hormones and analogues

Malta - English - Medicines Authority

ferring pharmaceuticals limited - desmopressin acetate - nasal drops, solution - desmopressin acetate 100 µg/ml - pituitary and hypothalamic hormones and analogues

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 4 ug in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.1 mg/ml (equivalent: desmopressin, qty 0.089 mg/ml) - spray, solution - excipient ingredients: dibasic sodium phosphate dihydrate; citric acid monohydrate; sodium chloride; purified water; benzalkonium chloride - diabetes insipidus:the treatment of adh-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria.,nocturnal enuresis: minirin nasal spray is indicated for the symptomatic treatment of primary nocturnal enuresis in patients who have normal ability to concentrate urine. minirin nasal spray should be used only in patients who are refractory to the enuresis alarm or in patients in whom enuresis alarm is contraindicated or inappropriate, and where the oral administration of desmopressin is not feasible.,renal concentrating capacity: by intranasal administration to adults and children as a diagnostic test to establish renal concentrating capacity.